Clinical trial
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid…
NCT00354523 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00354523 |
|---|---|
| Title | Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma |
| Official title | A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Solid Tumor, Thyroid Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate) |
| Enrollment | 21 |
| Start date | Dec 1, 2004 |
| Primary completion | Nov 1, 2006 |
| Completion | Aug 1, 2013 |
| First posted | Jul 20, 2006 |
| Last update posted | Dec 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: